NOVO NORDISK PHARMA OPERATIONS A/S — Credit Rating and Financial Key Figures

NOVO NORDISK PHARMA OPERATIONS A/S (CVR number: 32657222) is a company from GLADSAXE. The company reported a net sales of 109.6 mDKK in 2024, demonstrating a growth of 1.2 % compared to the previous year. The operating profit percentage was at 2.9 % (EBIT: 3.1 mDKK), while net earnings were 2298 kDKK. The profitability of the company measured by Return on Assets (ROA) was 4.4 %, which can be considered decent and Return on Equity (ROE) was 7.6 %, which can be considered decent. The equity ratio, a key indicator for solidity, stood at 31.4 %, a level that can be considered to be low. This means a higher proportion of debt in its capital structure, indicating a greater reliance on borrowed funds. NOVO NORDISK PHARMA OPERATIONS A/S's liquidity measured by quick ratio was 1.8 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.